FX 06

Drug Profile

FX 06

Alternative Names: FX 06-RI; FX 06-SS; FX06; FX06 HS; FX06 MRI; Peptide Bβ15-42

Latest Information Update: 19 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FIBREX Medical
  • Developer F4 Pharma; FIBREX Medical
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Cadherin 5 modulators; Fibrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Capillary leak syndrome; Delayed graft function; Shock; Systemic inflammatory response syndrome
  • Discontinued Reperfusion injury

Most Recent Events

  • 28 Jan 2014 Discontinued - Phase-II for Reperfusion injury in Europe (IV)
  • 01 Jan 2014 Phase-I clinical trials in Delayed graft function in Austria (IV)
  • 01 Jan 2014 Phase-I clinical trials in Shock in Austria (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top